Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew W Segar

Showing results (51-60 of 68) with videos related to

Pageof 7
Sort By:
American Journal of Preventive Cardiology|June 15, 2026
A polypill strategy for lipid lowering and anti-platelet therapy after acute coronary syndrome: A pilot randomized controlled trialJuan David Coellar, Neil Keshvani, Anand K Jain, et al.
European Journal of Heart Failure|October 24, 2022
Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trialKershaw V Patel, Muhammad Shahzeb Khan, Matthew W Segar, et al.
European Journal of Heart Failure|November 3, 2021
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemiaMatthew W Segar, Muhammad Shahzeb Khan, Kershaw V Patel, et al.
JACC. Heart Failure|November 8, 2025
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary StudyZainali Chunawala, Kershaw V Patel, Katelyn R Garcia, et al.
Journal of the American Heart Association|June 3, 2022
Validation of the WATCH-DM and TRS-HF<sub>DM</sub> Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort AnalysisMatthew W Segar, Kershaw V Patel, Anne S Hellkamp, et al.
JACC. Heart Failure|May 25, 2023
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure RiskMuhammad Shahzeb Khan, Matthew W Segar, Muhammad Shariq Usman, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
JACC. Heart Failure|April 28, 2023
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT TrialMuhammad Shahzeb Khan, Sumitabh Singh, Matthew W Segar, et al.
Circulation|November 11, 2023
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort AnalysisKershaw V Patel, Matthew W Segar, David C Klonoff, et al.
Circulation|December 15, 2020
Gender-Based Differences in Outcomes Among Resuscitated Patients With Out-of-Hospital Cardiac ArrestPurav Mody, Ambarish Pandey, Arthur S Slutsky, et al.
Pageof 7

Showing results (51-60 of 68) with videos related to

Sort By:
Pageof 7
American Journal of Preventive Cardiology|June 15, 2026
A polypill strategy for lipid lowering and anti-platelet therapy after acute coronary syndrome: A pilot randomized controlled trialJuan David Coellar, Neil Keshvani, Anand K Jain, et al.
European Journal of Heart Failure|October 24, 2022
Optimal cardiometabolic health and risk of heart failure in type 2 diabetes: an analysis from the Look AHEAD trialKershaw V Patel, Muhammad Shahzeb Khan, Matthew W Segar, et al.
European Journal of Heart Failure|November 3, 2021
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemiaMatthew W Segar, Muhammad Shahzeb Khan, Kershaw V Patel, et al.
JACC. Heart Failure|November 8, 2025
Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary StudyZainali Chunawala, Kershaw V Patel, Katelyn R Garcia, et al.
Journal of the American Heart Association|June 3, 2022
Validation of the WATCH-DM and TRS-HF<sub>DM</sub> Risk Scores to Predict the Risk of Incident Hospitalization for Heart Failure Among Adults With Type 2 Diabetes: A Multicohort AnalysisMatthew W Segar, Kershaw V Patel, Anne S Hellkamp, et al.
JACC. Heart Failure|May 25, 2023
Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure RiskMuhammad Shahzeb Khan, Matthew W Segar, Muhammad Shariq Usman, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
JACC. Heart Failure|April 28, 2023
Polypharmacy and Optimization of Guideline-Directed Medical Therapy in Heart Failure: The GUIDE-IT TrialMuhammad Shahzeb Khan, Sumitabh Singh, Matthew W Segar, et al.
Circulation|November 11, 2023
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: A Pooled Cohort AnalysisKershaw V Patel, Matthew W Segar, David C Klonoff, et al.
Circulation|December 15, 2020
Gender-Based Differences in Outcomes Among Resuscitated Patients With Out-of-Hospital Cardiac ArrestPurav Mody, Ambarish Pandey, Arthur S Slutsky, et al.
Pageof 7